Previous research has demonstrated that valproic acid can modulate the compromised mitochondrial function by suppressing the expression of mitochondrial elongation factor 1 (MIEF1), thus inhibiting the proliferation of breast cancer cells (Du et al., 2022). This evidence concerns the gene MIEF1 and breast carcinoma.